Clinical Trial Update: A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Penpulimab and Anlotinib with Nab-paclitaxel and Gemcitabine in metastatic pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Penpulimab

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Pancreatic Neoplasms | Phase 2 | Status: COMPLETED